CN105560314A - Narrowleaf screwtree root and rifampicin-containing compound drug for livestock and poultry - Google Patents
Narrowleaf screwtree root and rifampicin-containing compound drug for livestock and poultry Download PDFInfo
- Publication number
- CN105560314A CN105560314A CN201610063892.9A CN201610063892A CN105560314A CN 105560314 A CN105560314 A CN 105560314A CN 201610063892 A CN201610063892 A CN 201610063892A CN 105560314 A CN105560314 A CN 105560314A
- Authority
- CN
- China
- Prior art keywords
- drug
- rifampicin
- poultry
- livestock
- radix helicteris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title claims abstract description 18
- 229960001225 rifampicin Drugs 0.000 title claims abstract description 18
- 244000144977 poultry Species 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title abstract description 21
- 244000144972 livestock Species 0.000 title abstract description 4
- 241000933211 Helicteres jamaicensis Species 0.000 title abstract 3
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003640 drug residue Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 229940124350 antibacterial drug Drugs 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 description 19
- 239000004599 antimicrobial Substances 0.000 description 18
- 235000013330 chicken meat Nutrition 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 14
- 235000013594 poultry meat Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 102000006635 beta-lactamase Human genes 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 2
- 229960005229 ceftiofur Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000373 tazobactam sodium Drugs 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a narrowleaf screwtree root and rifampicin-containing compound drug for livestock and poultry. The compound drug is prepared from, by weight, 3-30 parts of rifampicin and 5-200 parts of narrowleaf screwtree roots. The raw materials are mixed evenly, prepared into powder or tablets or oral liquid or granules and added into livestock and poultry feedstuff according to the feedstuff addition amount of 0.1 g/kg-7 g/kg for feeding to reverse drug resistance of bacteria to antibacterial drugs, in this way, the treatment effect of the antibacterial drugs is improved, the medication cost and drug residues are substantially reduced, higher economic benefits are created for farmers, and the food safety of human beings is guaranteed.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, particularly relate to a kind of poultry compound medicine containing Radix Helicteris and rifampicin.
Background technology
Escherichia coli are common conditioned pathogens, also be the normal a kind of disease sent out, it can formerly have been carried out the coffin upon burial the multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis, also can secondary or mixedly to send out in virosis, causes huge economic loss to aquaculture.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, and the report about Drug Resistance of E. coli is also more.Research confirms, one of main mechanism of drug resistance produces beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be hydrolyzed beta-lactam nucleus more by force and rapidly, makes this kind of antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it not only to cephalo three generations and aztreonam drug resistance, and is crossing drug resistant to aminoglycoside, quinolones and sulfonamides, only to carbapenems, a mould alkene class medicaments insensitive.Many documents reported colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to comparatively pay close attention to.Inventor has carried out the detection of food animal source pathogenic bacterium ESBLs recently, extraction, enzyme press down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; show the colibacillary drug sensitive test of part ESBLs, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., in serious multidrug resistant.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and brings larger economic loss, and increase poultry drug residue risk to production.Therefore, the escherichia coli needing a kind of drug resistance to no matter whether in actual production badly can have the medicine of better therapeutical effect, and can shorten treatment course for the treatment of, reduce mortality rate, reduce economic loss and reduce drug residue, for raiser creates higher economic benefit, also ensureing that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine containing Radix Helicteris and rifampicin, it can kill antibacterial quickly, overcome large, the residual high and defect that cost is high of weak curative effect that antimicrobial drug treatment causes due to drug resistance problems, consumption, avoid that simple Chinese medicine sterilizing spectrum is narrow, sterilize slow problem.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine containing Radix Helicteris and rifampicin, is made up of the raw material of following weight portion: rifampicin 3-30 part, Radix Helicteris 5-200 part.Described Radix Helicteris belongs to Sterculiaceae Radix Helicteris and belongs to.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Radix Helicteris was pulverized 60 mesh sieves, then mixes with pulverous antimicrobial drug, is prepared into powder, tablet, oral liquid or granule according to a conventional method.
For the drug resistance problems that current poultry coli-infection exists, inventor utilizes Guangxi Special Traditional Chinese Medicine Radix Helicteris and antimicrobial drug to form compound medicine.Research proves, after adding Radix Helicteris in antimicrobial drug, can reverse bacterial to the drug resistance of antimicrobial drug, thus improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made powder, tablet, oral liquid or granule, add in animal and fowl fodder according to the 0.1-7g principal agent/addition of kg feedstuff and feed, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also ensure that food safety simultaneously.
Detailed description of the invention
One, Radix Helicteris is to the drug resistance inversion Effect study of antimicrobial drug
Antimicrobial drug itself has the colibacillary effect for the treatment of, but has stronger drug resistance due to the escherichia coli producing ESBLs drug resistant gene, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify the drug resistance inversion effect of Radix Helicteris to antimicrobial drug, 96 orifice plates adopt microtest tube doubling dilution, first determine antimicrobial drug to producing the minimal inhibitory concentration of e. coli strains of ESBLs drug resistant gene and Radix Helicteris to the subinhibitory concentration producing ESBLs drug resistant gene e. coli strains, the Radix Helicteris then adding subinhibitory concentration in the medium reuses microtest tube doubling dilution and cultivates the minimal inhibitory concentration measuring antimicrobial drug; Continuous passage method is utilized to carry out Secondary Culture to product ESBLs drug resistant gene e. coli strains in the culture medium being added with same subinhibitory concentration Radix Helicteris and same concentration antimicrobial drug, until the antimicrobial drug minimal inhibitory concentration observed diminishes more than 4 times compared with before going down to posterity, can be judged as that Radix Helicteris has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.25g/mL) Radix Helicteris goes down to posterity and causes the change (mg/mL) of product ESBLs escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times to the minimal inhibitory concentration of antibiotic-resistance E. coli, can judge that Radix Helicteris has drug resistance inversion effect to product ESBLs drug resistant gene escherichia coli.
Two, the application example of compound medicine of the present invention
Prepare embodiment 1-embodiment 4 in accordance with the following methods: after Radix Helicteris being pulverized 60 mesh sieves, based on raw material, then with pulverous antimicrobial drug by weight ratio put into blender and mix, according to a conventional method, compound medicine is prepared into formulation products.
The formula of table 2 embodiment 1-4 and preparation dosage form
| Numbering | Antimicrobial drug | Radix Helicteris | Dosage form |
| Embodiment 1 | Rifampicin 3g | 120g | Tablet |
| Embodiment 2 | Rifampicin 10g | 90g | Powder |
| Embodiment 3 | Rifampicin 14g | 40g | Oral liquid |
| Embodiment 4 | Rifampicin 20g | 180g | Granule |
Above-described embodiment is obtained compound medicine product and has carried out following experiment by inventor:
The compound medicine product of embodiment 1-4 gained is to the efficacy experiment of chicken escherichia coil disease
Clinical symptoms: Guigang, Guangxi chicken house, 25 Day-old Broiler Chickens, there is fragmentary death in chicken group, cuts open the indivedual chicken of inspection and occur the pathological change of bag pericardium liver, typical bacillus coli feature.
Laboratory diagnosis: get pathologic liver dye sheet, Gram’s staining, basis of microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivated by escherichia coli, biochemical test is differentiated, judges that chicken infects as bacillus coli, pcr amplification, proves to produce the ESBLs drug resistant gene having TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, first group with the addition administration of embodiment 1 according to 7g/kg feedstuff, second group with the addition administration of embodiment 2 according to 2g/kg feedstuff, 3rd group with the addition administration of embodiment 3 according to 0.8g/kg feedstuff, the 4th group with the addition administration of embodiment 4 according to 2g/kg feedstuff; 5th group with the addition administration of rifampicin powder according to 0.2g/kg feedstuff, the 6th group with the addition administration of the thick powder of Radix Helicteris according to 4g/kg feedstuff; Above six groups of therapeutic regimens all continue use 5 days.
Staining effect: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, and continue use 3 days, chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken death, and continue use 3 days, chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, and continue use 3 days, chicken death phenomenon is not still effectively controlled.Visible, the compound medicine curative effect containing Radix Helicteris is better than folk prescription.
Claims (3)
1. contain a poultry compound medicine for Radix Helicteris and rifampicin, it is characterized in that, be made up of the raw material of following weight portion: rifampicin 3-30 part, Radix Helicteris 5-200 part.
2. the poultry compound medicine containing Radix Helicteris and rifampicin according to claim 1, it is characterized in that, described compound medicine is made up of the raw material of following weight portion: rifampicin 3-30 part and Radix Helicteris 40-180 part.
3. the poultry compound medicine containing Radix Helicteris and rifampicin according to any one of claim 1-2, it is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610063892.9A CN105560314A (en) | 2016-01-29 | 2016-01-29 | Narrowleaf screwtree root and rifampicin-containing compound drug for livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610063892.9A CN105560314A (en) | 2016-01-29 | 2016-01-29 | Narrowleaf screwtree root and rifampicin-containing compound drug for livestock and poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105560314A true CN105560314A (en) | 2016-05-11 |
Family
ID=55871332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610063892.9A Pending CN105560314A (en) | 2016-01-29 | 2016-01-29 | Narrowleaf screwtree root and rifampicin-containing compound drug for livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105560314A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134833A (en) * | 1995-12-22 | 1996-11-06 | 谢发林 | Composite pharmaceutics for curing dysentery |
| CN1686307A (en) * | 2005-03-21 | 2005-10-26 | 山东农业大学 | Composition for preventing and treating poultry bacterial disease |
-
2016
- 2016-01-29 CN CN201610063892.9A patent/CN105560314A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134833A (en) * | 1995-12-22 | 1996-11-06 | 谢发林 | Composite pharmaceutics for curing dysentery |
| CN1686307A (en) * | 2005-03-21 | 2005-10-26 | 山东农业大学 | Composition for preventing and treating poultry bacterial disease |
Non-Patent Citations (1)
| Title |
|---|
| 赵秀贞: "《青草药彩色图谱》", 30 April 1997, 福建科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103977090B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and florfenicol | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN103989730A (en) | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN105617383A (en) | Compound livestock and poultry drug containing garden balsam stems and beta-lactam antibacterial drug | |
| CN104435012A (en) | Pteris multifida and florfenicol-containing compound drug for livestock and poultry | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN103948912B (en) | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and colistin | |
| CN103948657A (en) | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN105560314A (en) | Narrowleaf screwtree root and rifampicin-containing compound drug for livestock and poultry | |
| CN103933088A (en) | Method for treating Escherichia coli infection diseases by using creat and antibacterial agents | |
| CN104436161A (en) | Pteris multifida and colistin-containing compound drug for livestock and poultry | |
| CN103933085A (en) | Method for treating Escherichia coli infection diseases by using creat and fosfomycin | |
| CN104306421A (en) | Balsamiferou Blumea herb and florfenicol containing compound medicine for livestock and poultry | |
| CN104162145A (en) | Acalypha australis L. and colistin-containing compound medicine for livestock and poultry | |
| CN103933087A (en) | Method for treating Escherichia coli infection diseases by using creat and amikacin | |
| CN104840502A (en) | Composition containing epimedium herb and mequindox and used for livestock and poultry, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |
|
| RJ01 | Rejection of invention patent application after publication |